India is proposing a series of reforms and incentives aimed at expanding its generic drug footprint in US amid ongoing bilateral trade talks, Mint reported. India’s proposals include sharply reduced pricing for complex generic medicines. Patent reforms to curb 'evergreening' practices by US pharma and tariff exemptions for critical drugs imported from the US, are among the other proposals.